Antimalarial drug resistance in Bangladesh, 1996-2012

Ubydul Haque, Gregory E. Glass, Waziul Haque, Nazrul Islam, Shyamal Roy, Jahirul Karim, Harald Noedl

Research output: Contribution to journalArticle

Abstract

Malaria remains an important health problem in Bangladesh, with approximately 14 million people at risk. Antimalarial drug resistance is a major obstacle to the control of malaria in endemic countries. In 2012, Bangladesh reported an estimated 29 522 malaria episodes, of which 94% were reported as being caused by Plasmodium falciparum. In this study, we reviewed and summarized antimalarial drug resistance data from Bangladesh published until June 2013. We searched published sources for data referring to any type of P. falciparum drug resistance (in vivo, in vitro, or molecular) and found 169 articles published in peer-reviewed journals. Of these, 143 articles were excluded because they did not meet our inclusion criteria. After detailed review of the remaining 26 articles, 14 were selected for evaluation. Published studies indicate that P. falciparum shows varying levels of resistance to chloroquine, mefloquine and sulfadoxine-pyrimethamine. Combination therapy of chloroquine and primaquine has proven ineffective and combinations of sulfadoxine-pyrimethamine with either quinine or chloroquine have also shown poor efficacy. Recent studies indicate that artemisinin derivatives, such as artesunate, remain highly efficacious in treating P. falciparum malaria. Available data suggest that artemisinins, quinine, doxycyline, mefloquine-artesunate and azithromycin-artesunate combination therapy remain efficacious in the treatment of P. falciparum malaria in Bangladesh.

Original languageEnglish (US)
Article numbertrt088
Pages (from-to)745-752
Number of pages8
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume107
Issue number12
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Bangladesh
Antimalarials
Drug Resistance
Chloroquine
Plasmodium falciparum
Malaria
Quinine
Falciparum Malaria
Artemisinins
Primaquine
Mefloquine
Azithromycin
Information Storage and Retrieval
Health
Therapeutics
artesunate

Keywords

  • Bangladesh
  • Drug
  • Malaria
  • Resistance

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

Haque, U., Glass, G. E., Haque, W., Islam, N., Roy, S., Karim, J., & Noedl, H. (2013). Antimalarial drug resistance in Bangladesh, 1996-2012. Transactions of the Royal Society of Tropical Medicine and Hygiene, 107(12), 745-752. [trt088]. https://doi.org/10.1093/trstmh/trt088

Antimalarial drug resistance in Bangladesh, 1996-2012. / Haque, Ubydul; Glass, Gregory E.; Haque, Waziul; Islam, Nazrul; Roy, Shyamal; Karim, Jahirul; Noedl, Harald.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 107, No. 12, trt088, 12.2013, p. 745-752.

Research output: Contribution to journalArticle

Haque, U, Glass, GE, Haque, W, Islam, N, Roy, S, Karim, J & Noedl, H 2013, 'Antimalarial drug resistance in Bangladesh, 1996-2012', Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 107, no. 12, trt088, pp. 745-752. https://doi.org/10.1093/trstmh/trt088
Haque, Ubydul ; Glass, Gregory E. ; Haque, Waziul ; Islam, Nazrul ; Roy, Shyamal ; Karim, Jahirul ; Noedl, Harald. / Antimalarial drug resistance in Bangladesh, 1996-2012. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 2013 ; Vol. 107, No. 12. pp. 745-752.
@article{b667b66644654049ae754172aae46143,
title = "Antimalarial drug resistance in Bangladesh, 1996-2012",
abstract = "Malaria remains an important health problem in Bangladesh, with approximately 14 million people at risk. Antimalarial drug resistance is a major obstacle to the control of malaria in endemic countries. In 2012, Bangladesh reported an estimated 29 522 malaria episodes, of which 94{\%} were reported as being caused by Plasmodium falciparum. In this study, we reviewed and summarized antimalarial drug resistance data from Bangladesh published until June 2013. We searched published sources for data referring to any type of P. falciparum drug resistance (in vivo, in vitro, or molecular) and found 169 articles published in peer-reviewed journals. Of these, 143 articles were excluded because they did not meet our inclusion criteria. After detailed review of the remaining 26 articles, 14 were selected for evaluation. Published studies indicate that P. falciparum shows varying levels of resistance to chloroquine, mefloquine and sulfadoxine-pyrimethamine. Combination therapy of chloroquine and primaquine has proven ineffective and combinations of sulfadoxine-pyrimethamine with either quinine or chloroquine have also shown poor efficacy. Recent studies indicate that artemisinin derivatives, such as artesunate, remain highly efficacious in treating P. falciparum malaria. Available data suggest that artemisinins, quinine, doxycyline, mefloquine-artesunate and azithromycin-artesunate combination therapy remain efficacious in the treatment of P. falciparum malaria in Bangladesh.",
keywords = "Bangladesh, Drug, Malaria, Resistance",
author = "Ubydul Haque and Glass, {Gregory E.} and Waziul Haque and Nazrul Islam and Shyamal Roy and Jahirul Karim and Harald Noedl",
year = "2013",
month = "12",
doi = "10.1093/trstmh/trt088",
language = "English (US)",
volume = "107",
pages = "745--752",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Antimalarial drug resistance in Bangladesh, 1996-2012

AU - Haque, Ubydul

AU - Glass, Gregory E.

AU - Haque, Waziul

AU - Islam, Nazrul

AU - Roy, Shyamal

AU - Karim, Jahirul

AU - Noedl, Harald

PY - 2013/12

Y1 - 2013/12

N2 - Malaria remains an important health problem in Bangladesh, with approximately 14 million people at risk. Antimalarial drug resistance is a major obstacle to the control of malaria in endemic countries. In 2012, Bangladesh reported an estimated 29 522 malaria episodes, of which 94% were reported as being caused by Plasmodium falciparum. In this study, we reviewed and summarized antimalarial drug resistance data from Bangladesh published until June 2013. We searched published sources for data referring to any type of P. falciparum drug resistance (in vivo, in vitro, or molecular) and found 169 articles published in peer-reviewed journals. Of these, 143 articles were excluded because they did not meet our inclusion criteria. After detailed review of the remaining 26 articles, 14 were selected for evaluation. Published studies indicate that P. falciparum shows varying levels of resistance to chloroquine, mefloquine and sulfadoxine-pyrimethamine. Combination therapy of chloroquine and primaquine has proven ineffective and combinations of sulfadoxine-pyrimethamine with either quinine or chloroquine have also shown poor efficacy. Recent studies indicate that artemisinin derivatives, such as artesunate, remain highly efficacious in treating P. falciparum malaria. Available data suggest that artemisinins, quinine, doxycyline, mefloquine-artesunate and azithromycin-artesunate combination therapy remain efficacious in the treatment of P. falciparum malaria in Bangladesh.

AB - Malaria remains an important health problem in Bangladesh, with approximately 14 million people at risk. Antimalarial drug resistance is a major obstacle to the control of malaria in endemic countries. In 2012, Bangladesh reported an estimated 29 522 malaria episodes, of which 94% were reported as being caused by Plasmodium falciparum. In this study, we reviewed and summarized antimalarial drug resistance data from Bangladesh published until June 2013. We searched published sources for data referring to any type of P. falciparum drug resistance (in vivo, in vitro, or molecular) and found 169 articles published in peer-reviewed journals. Of these, 143 articles were excluded because they did not meet our inclusion criteria. After detailed review of the remaining 26 articles, 14 were selected for evaluation. Published studies indicate that P. falciparum shows varying levels of resistance to chloroquine, mefloquine and sulfadoxine-pyrimethamine. Combination therapy of chloroquine and primaquine has proven ineffective and combinations of sulfadoxine-pyrimethamine with either quinine or chloroquine have also shown poor efficacy. Recent studies indicate that artemisinin derivatives, such as artesunate, remain highly efficacious in treating P. falciparum malaria. Available data suggest that artemisinins, quinine, doxycyline, mefloquine-artesunate and azithromycin-artesunate combination therapy remain efficacious in the treatment of P. falciparum malaria in Bangladesh.

KW - Bangladesh

KW - Drug

KW - Malaria

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84887969582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887969582&partnerID=8YFLogxK

U2 - 10.1093/trstmh/trt088

DO - 10.1093/trstmh/trt088

M3 - Article

VL - 107

SP - 745

EP - 752

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 12

M1 - trt088

ER -